Intellectual Property In India: Novartis Gleevec Suit Is First Challenge To Law Restricting New Formulation Patents (Part 2 of 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis argues India’s interpretation of the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights agreement is too strict and focuses too much on efficacy to the exclusion of bioavailability.
You may also be interested in...
Indian Court Hands Novartis Setback In Gleevec Patent Case
Novartis suffered a major blow Aug. 6 when an Indian court dismissed its challenge of a key government provision that blocks the company from obtaining a patent for its oncologic Gleevec (imatinib)
Indian Court Hands Novartis Setback In Gleevec Patent Case
Novartis says decision will have innovation, intellectual property repercussions for other pharma firms operating in India.
Indian Court Hands Novartis Setback In Gleevec Patent Case
Novartis says decision will have innovation, intellectual property repercussions for other pharma firms operating in India.